Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

RS, Herbst; YL, Wu; T, John; C, Grohe; M, Majem; J, Wang; T, Kato; JW, Goldman; K, Laktionov; SW, Kim; CJ, Yu; HV, Vu; S, Lu; KY, Lee; G, Mukhametshina; C, Akewanlop; Marinis F, de; L, Bonanno; M, Domine; FA, Shepherd; D, Urban; X, Huang; A, Bolanos; M, Stachowiak; M, Tsuboi

doi:10.1200/jco.22.02186

Public

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Shared by NobleBlocks on Jan 31, 2023 • 12:00 AM UTC

Authors:

Herbst RS

Wu YL

John T

Abstract

Purpose The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resectio...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!